Aethlon medical reports positive results from an in vitro binding study of its hemopurifier® in removing extracellular vesicles from cancer patient plasma

Translational study provides pre-clinical evidence to support the design of a phase 1 study of the hemopurifier in cancer patients with solid tumors treated with anti-pd-1 antibodies san diego , may 10, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its hemopurifier® in removing extracellular vesicles (evs) from plasma. the translational study provides pre-clinical evidence to support aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the hemopurifier in patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® or opdivo®.
AEMD Ratings Summary
AEMD Quant Ranking